Disease_NN progression_NN modeling_NN from_IN historical_JJ clinical_JJ databases_NNS
This_DT paper_NN considers_VBZ the_DT problem_NN of_IN modeling_NN disease_NN progression_NN from_IN historical_JJ clinical_JJ databases_NNS ,_, with_IN the_DT ultimate_JJ objective_NN of_IN stratifying_VBG patients_NNS into_IN groups_NNS with_IN clearly_RB distinguishable_JJ prognoses_NNS or_CC suitability_NN for_IN different_JJ treatment_NN strategies_NNS ._.
To_TO meet_VB this_DT objective_NN ,_, we_PRP describe_VBP a_DT procedure_NN that_WDT first_RB fits_VBZ clinical_JJ variables_NNS measured_VBN over_IN time_NN to_TO a_DT disease_NN progression_NN model_NN ._.
The_DT resulting_VBG parameter_NN estimates_NNS are_VBP then_RB used_VBN as_IN the_DT basis_NN for_IN a_DT stepwise_JJ clustering_NN procedure_NN to_TO stratify_VB patients_NNS into_IN groups_NNS with_IN distinct_JJ survival_NN characteristics_NNS ._.
As_IN a_DT practical_JJ illustration_NN ,_, we_PRP apply_VBP this_DT procedure_NN to_TO survival_NN prediction_NN ,_, using_VBG a_DT liver_NN transplant_NN database_NN from_IN the_DT National_NNP Institute_NNP of_IN Diabetes_NNP and_CC Digestive_NNP and_CC Kidney_NNP Diseases_NNP -LRB-_-LRB- NIDDK_NNP -RRB-_-RRB- ._.
s_NN in_IN Fig._NNP 3_CD show_VBP the_DT corresponding_JJ normal_JJ quantile-quantile_NN -LRB-_-LRB- Q-Q_NN -RRB-_-RRB- plots_NNS for_IN the_DT raw_JJ and_CC transformed_VBN data_NNS sequences_NNS ,_, which_WDT provide_VBP an_DT indication_NN of_IN the_DT distributional_JJ character_NN of_IN these_DT data_NNS sequences_NNS =_JJ -_: =[_NN 3_CD -RRB-_-RRB- -_: =_SYM -_: ._.
In_IN particular_JJ ,_, normally_RB distributed_VBN data_NNS should_MD exhibit_VB a_DT linear_JJ Q-Q_NN plot_NN ,_, much_RB like_IN the_DT one_CD seen_VBN in_IN the_DT lower_JJR right_NN for_IN the_DT log-transformed_JJ ALT_NN values_NNS ._.
This_DT behavior_NN suggests_VBZ that_IN the_DT ALT_NN values_NNS ha_VBP
g_NN values_NNS ,_, while_IN 9_CD of_IN these_DT variables_NNS exhibit_VBP more_JJR than_IN 50_CD %_NN missing_JJ values_NNS ._.
These_DT observations_NNS play_VBP a_DT key_JJ role_NN in_IN variable_JJ selection_NN ,_, considered_VBN next_JJ ._.
3_LS ._.
VARIABLE_NNP SELECTION_NNP As_IN Guyon_NNP and_CC Elisseeff_NNP note_NN =_JJ -_: =[_NN 6_CD -RRB-_-RRB- -_: =_JJ -_: ,_, the_DT problems_NNS of_IN variable_NN and_CC feature_NN selection_NN have_VBP become_VBN the_DT focus_NN of_IN much_JJ research_NN as_IN the_DT analysis_NN of_IN larger_JJR and_CC larger_JJR datasets_NNS has_VBZ become_VBN more_RBR common_JJ and_CC more_RBR important_JJ ._.
Also_RB ,_, it_PRP is_VBZ known_VBN that_IN
ression_NN patterns_NNS ._.
This_DT clustering_NN problem_NN can_MD be_VB approached_VBN in_IN many_JJ different_JJ ways_NNS ,_, and_CC we_PRP have_VBP adopted_VBN a_DT variant_NN of_IN the_DT Partitioning_NN Around_IN Medoids_NNS -LRB-_-LRB- PAM_NNS -RRB-_-RRB- algorithm_NN described_VBN by_IN Kaufman_NNP and_CC Rousseeuw_NNP =_SYM -_: =[_NN 10_CD -RRB-_-RRB- -_: =_JJ -_: ,_, based_VBN on_IN their_PRP$ extension_NN for_IN large_JJ datasets_NNS -LRB-_-LRB- CLARA_NN -RRB-_-RRB- ._.
Specifically_RB ,_, like_IN CLARA_NNP ,_, the_DT algorithm_NN used_VBN here_RB selects_VBZ random_JJ subsamples_NNS from_IN the_DT original_JJ dataset_NN ,_, applies_VBZ the_DT PAM_NNS algorithm_NN to_TO cluster_VB this_DT
ij_NN -LRB-_-LRB- Σ_NN †_FW i_FW +_CC Σ_FW †_FW j_NN -RRB-_-RRB- Qij_NN -LRB-_-LRB- ˜vi_FW −_FW ˜vj_FW -RRB-_-RRB- ._.
-LRB-_-LRB- 5_CD -RRB-_-RRB- Here_RB ,_, Σi_NN represents_VBZ the_DT covariance_NN matrix_NN for_IN the_DT -LCB-_-LRB- a_DT ,_, b_NN ,_, m_NN ,_, ∆_NN -RCB-_-RRB- parameters_NNS estimated_VBN for_IN patient_NN i_FW ,_, the_DT superscript_JJ †_NN denotes_VBZ the_DT Moore-Penrose_NNP generalized_JJ inverse_NN =_JJ -_: =[_NN 1_CD -RRB-_-RRB- -_: =_JJ -_: ,_, and_CC the_DT matrix_NN Qij_NN accounts_VBZ for_IN the_DT fact_NN that_IN not_RB all_DT model_JJ parameters_NNS are_VBP defined_VBN for_IN all_DT patients_NNS ._.
In_IN particular_JJ ,_, note_VBP that_IN the_DT parameters_NNS m_NN and_CC ∆_NN are_VBP not_RB defined_VBN for_IN any_DT clinical_JJ variable_NN that_WDT is_VBZ
urally_RB ,_, this_DT ranking_NN is_VBZ best_RB done_VBN by_IN a_DT skilled_JJ clinician_NN ,_, although_IN published_VBN results_NNS in_IN the_DT medical_JJ literature_NN can_MD also_RB be_VB useful_JJ in_IN making_VBG tentative_JJ rankings_NNS ._.
For_IN example_NN ,_, both_DT Johnston_NNP -LRB-_-LRB- 9_CD -RRB-_-RRB- and_CC Blei_NN =_JJ -_: =[_NN 2_CD -RRB-_-RRB- -_: =_SYM -_: discuss_VB the_DT interpretation_NN of_IN alkaline_NN phosphatase_NN ,_, SGOT_NNP -LRB-_-LRB- AST_NNP -RRB-_-RRB- ,_, and_CC bilirubin_NN as_IN indicators_NNS of_IN liver_NN damage_NN ._.
It_PRP is_VBZ worth_JJ emphasizing_VBG ,_, however_RB ,_, that_IN strict_JJ reliance_NN on_IN variables_NNS that_WDT are_VBP known_VBN to_TO be_VB c_NN
to_TO determine_VB treatment_NN and_CC predict_VBP outcome_NN ._.
In_IN prostate_NN cancer_NN ,_, for_IN example_NN ,_, a_DT linear_JJ model_NN of_IN a_DT single_JJ variable_NN ,_, a_DT laboratory_NN test_NN known_VBN as_IN PSA_NN ,_, has_VBZ been_VBN shown_VBN to_TO have_VB predictive_JJ value_NN for_IN survival_NN =_JJ -_: =[_NN 4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Recognizing_VBG the_DT limitations_NNS of_IN linear_JJ models_NNS for_IN realistic_JJ clinical_JJ variables_NNS ,_, Hellriegel_NNP et_FW al._FW developed_VBD a_DT segmented_JJ linear_JJ model_NN of_IN multiple_JJ sclerosis_NN progression_NN -LRB-_-LRB- 7_CD -RRB-_-RRB- ._.
This_DT paper_NN describes_VBZ our_PRP$ ef_NN
redictive_JJ value_NN for_IN survival_NN -LRB-_-LRB- 4_CD -RRB-_-RRB- ._.
Recognizing_VBG the_DT limitations_NNS of_IN linear_JJ models_NNS for_IN realistic_JJ clinical_JJ variables_NNS ,_, Hellriegel_NNP et_FW al._FW developed_VBD a_DT segmented_JJ linear_JJ model_NN of_IN multiple_JJ sclerosis_NN progression_NN =_JJ -_: =[_NN 7_CD -RRB-_-RRB- -_: =_SYM -_: ._.
This_DT paper_NN describes_VBZ our_PRP$ efforts_NNS to_TO develop_VB a_DT more_RBR comprehensive_JJ data-mining_JJ tool_NN 1_CD for_IN the_DT analysis_NN of_IN disease_NN progression_NN patterns_NNS ,_, with_IN the_DT goal_NN of_IN producing_VBG results_NNS that_WDT can_MD be_VB used_VBN to_TO guide_VB tre_NN
greater_JJR than_IN t_NN ,_, i.e._FW S_NN -LRB-_-LRB- t_NN -RRB-_-RRB- =_JJ P_NN -LCB-_-LRB- T_NN -RRB-_-RRB- t_NN -RCB-_-RRB- =_JJ 1_CD −_NN F_NN -LRB-_-LRB- t_NN -RRB-_-RRB- and_CC Kaplan-Meier_NN survival_NN analysis_NN constructs_NNS an_DT estimate_NN ˆ_NN S_NN -LRB-_-LRB- t_NN -RRB-_-RRB- of_IN the_DT survival_NN curve_NN S_NN -LRB-_-LRB- t_NN -RRB-_-RRB- that_WDT is_VBZ easily_RB computed_VBN from_IN the_DT available_JJ censored_VBN data_NN =_JJ -_: =[_NN 8_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Specifically_RB ,_, let_VB u1_NN -LRB-_-LRB- u2_NN -LRB-_-LRB- ..._: -LRB-_-LRB- uk_RB be_VB the_DT distinct_JJ values_NNS in_IN the_DT sequence_NN -LCB-_-LRB- ti_NN -RCB-_-RRB- ,_, recognizing_VBG that_IN repeated_VBN values_NNS commonly_RB arise_VBP ._.
For_IN each_DT uj_NN ,_, let_VB rj_NN denote_VB the_DT number_NN of_IN patients_NNS still_RB at_IN risk_NN a_DT
h_NN like_IN the_DT one_CD seen_VBN in_IN the_DT lower_JJR right_NN for_IN the_DT log-transformed_JJ ALT_NN values_NNS ._.
This_DT behavior_NN suggests_VBZ that_IN the_DT ALT_NN values_NNS have_VBP an_DT approximate_JJ lognormal_JJ distribution_NN ,_, a_DT characterization_NN that_WDT is_VBZ well-known_NN =_JJ -_: =[_NN 9_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Even_RB in_IN cases_NNS where_WRB the_DT log_NN transformation_NN does_VBZ not_RB bring_VB the_DT data_NNS distribution_NN to_TO normality_NN ,_, it_PRP often_RB greatly_RB reduces_VBZ the_DT range_NN of_IN variation_NN and_CC improves_VBZ distributional_JJ symmetry_NN ,_, so_IN it_PRP is_VBZ frequentl_NN
can_MD now_RB be_VB tied_VBN to_TO individual_JJ genes_NNS or_CC groups_NNS of_IN genes_NNS ,_, so_IN that_IN laboratory_NN analysis_NN of_IN genetics_NNS can_MD be_VB used_VBN to_TO guide_VB prognosis_NN and_CC treatment_NN ._.
This_DT is_VBZ becoming_VBG the_DT case_NN with_IN breast_NN cancer_NN ,_, for_IN example_NN =_JJ -_: =[_NN 11_CD -RRB-_-RRB- -_: =_SYM -_: ._.
In_IN other_JJ Robert_NNP J._NNP Kingan_NNP ProSanos_NNP Corporation_NNP Harrisburg_NNP ,_, PA_NN ,_, USA_NN bob_NN ._.
kingan_VB @prosanos.com_NNP Alan_NNP Hochberg_NNP ProSanos_NNP Corporation_NNP Harrisburg_NNP ,_, PA_NN ,_, USA_NN alan_NN ._.
hochberg_FW @prosanos.com_FW diseases_NNS ,_, the_DT genetic_JJ p_NN
or_CC possible_JJ differences_NNS between_IN them_PRP ._.
For_IN example_NN ,_, it_PRP is_VBZ known_VBN that_IN the_DT age_NN of_IN the_DT organ_NN donor_NN ,_, age_NN of_IN the_DT recipient_JJ at_IN time_NN of_IN transplant_NN ,_, and_CC recipient_JJ race_NN all_DT relate_VBP to_TO liver_NN transplant_NN duration_NN -LRB-_-LRB- =_JJ -_: =[_NN 12_CD -RRB-_-RRB- -_: =_JJ -_: ,_, -LRB-_-LRB- 13_CD -RRB-_-RRB- and_CC -LRB-_-LRB- 14_CD -RRB-_-RRB- ,_, respectively_RB -RRB-_-RRB- ._.
The_DT ages_NNS and_CC races_NNS of_IN the_DT patients_NNS in_IN the_DT two_CD clusters_NNS with_IN the_DT largest_JJS estimated_VBN survival_NN difference_NN at_IN 150_CD weeks_NNS were_VBD compared_VBN ._.
While_IN no_DT significant_JJ difference_NN was_VBD fo_FW
sible_JJ differences_NNS between_IN them_PRP ._.
For_IN example_NN ,_, it_PRP is_VBZ known_VBN that_IN the_DT age_NN of_IN the_DT organ_NN donor_NN ,_, age_NN of_IN the_DT recipient_JJ at_IN time_NN of_IN transplant_NN ,_, and_CC recipient_JJ race_NN all_DT relate_VBP to_TO liver_NN transplant_NN duration_NN -LRB-_-LRB- -LRB-_-LRB- 12_CD -RRB-_-RRB- ,_, =_JJ -_: =[_NN 13_CD -RRB-_-RRB- -_: =_JJ -_: and_CC -LRB-_-LRB- 14_CD -RRB-_-RRB- ,_, respectively_RB -RRB-_-RRB- ._.
The_DT ages_NNS and_CC races_NNS of_IN the_DT patients_NNS in_IN the_DT two_CD clusters_NNS with_IN the_DT largest_JJS estimated_VBN survival_NN difference_NN at_IN 150_CD weeks_NNS were_VBD compared_VBN ._.
While_IN no_DT significant_JJ difference_NN was_VBD found_VBN in_IN
ferences_NNS between_IN them_PRP ._.
For_IN example_NN ,_, it_PRP is_VBZ known_VBN that_IN the_DT age_NN of_IN the_DT organ_NN donor_NN ,_, age_NN of_IN the_DT recipient_JJ at_IN time_NN of_IN transplant_NN ,_, and_CC recipient_JJ race_NN all_DT relate_VBP to_TO liver_NN transplant_NN duration_NN -LRB-_-LRB- -LRB-_-LRB- 12_CD -RRB-_-RRB- ,_, -LRB-_-LRB- 13_CD -RRB-_-RRB- and_CC =_JJ -_: =[_NN 14_CD -RRB-_-RRB- -_: =_JJ -_: ,_, respectively_RB -RRB-_-RRB- ._.
The_DT ages_NNS and_CC races_NNS of_IN the_DT patients_NNS in_IN the_DT two_CD clusters_NNS with_IN the_DT largest_JJS estimated_VBN survival_NN difference_NN at_IN 150_CD weeks_NNS were_VBD compared_VBN ._.
While_IN no_DT significant_JJ difference_NN was_VBD found_VBN in_IN the_DT dist_NN
arger_JJR and_CC larger_JJR datasets_NNS has_VBZ become_VBN more_RBR common_JJ and_CC more_RBR important_JJ ._.
Also_RB ,_, it_PRP is_VBZ known_VBN that_IN inclusion_NN of_IN irrelevant_JJ variables_NNS in_IN cluster_NN analysis_NN can_MD cause_VB clustering_NN results_NNS to_TO degrade_VB significantly_RB =_JJ -_: =[_NN 5_CD ,_, 15_CD -RRB-_-RRB- -_: =_JJ -_: ,_, further_RB emphasizing_VBG the_DT importance_NN of_IN careful_JJ variable_JJ selection_NN ._.
The_DT following_VBG paragraphs_NNS briefly_RB describe_VBP a_DT five_CD step_NN variable_JJ selection_NN strategy_NN that_IN we_PRP have_VBP found_VBN useful_JJ in_IN analyzing_VBG historical_JJ
The_DT NIDDK_NNP database_NN The_DT NIDDK_NN liver_NN transplant_NN database_NN is_VBZ a_DT collection_NN of_IN information_NN from_IN a_DT seven_CD year_NN prospective_JJ study_NN of_IN 1563_CD candidates_NNS for_IN liver_NN transplants_NNS from_IN three_CD different_JJ medical_JJ centers_NNS =_JJ -_: =[_NN 17_CD -RRB-_-RRB- -_: =_SYM -_: ._.
This_DT database_NN consists_VBZ of_IN 88_CD individual_JJ datasets_NNS ,_, linked_VBN by_IN certain_JJ common_JJ key_JJ variables_NNS like_IN the_DT patient_NN ID_NN field_NN that_WDT uniquely_RB specifies_VBZ one_CD of_IN the_DT 1563_CD transplant_NN candidates_NNS ._.
In_IN addition_NN ,_, since_IN s_NN
